PL3948294T3 - Zastosowanie folistatyny w przewidywaniu ryzyka cukrzycy typu 2 - Google Patents

Zastosowanie folistatyny w przewidywaniu ryzyka cukrzycy typu 2

Info

Publication number
PL3948294T3
PL3948294T3 PL20715859.3T PL20715859T PL3948294T3 PL 3948294 T3 PL3948294 T3 PL 3948294T3 PL 20715859 T PL20715859 T PL 20715859T PL 3948294 T3 PL3948294 T3 PL 3948294T3
Authority
PL
Poland
Prior art keywords
follistatin
type
risk prediction
diabetes risk
diabetes
Prior art date
Application number
PL20715859.3T
Other languages
English (en)
Inventor
Yang DE MARINIS
Original Assignee
Lundoch Diagnostics AB
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Lundoch Diagnostics AB filed Critical Lundoch Diagnostics AB
Publication of PL3948294T3 publication Critical patent/PL3948294T3/pl

Links

Classifications

    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
    • G01N33/6893—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids related to diseases not provided for elsewhere
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/66—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving blood sugars, e.g. galactose
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/72—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving blood pigments, e.g. haemoglobin, bilirubin or other porphyrins; involving occult blood
    • G01N33/721—Haemoglobin
    • G01N33/723—Glycosylated haemoglobin
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/74—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving hormones or other non-cytokine intercellular protein regulatory factors such as growth factors, including receptors to hormones and growth factors
    • G—PHYSICS
    • G16—INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR SPECIFIC APPLICATION FIELDS
    • G16B—BIOINFORMATICS, i.e. INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR GENETIC OR PROTEIN-RELATED DATA PROCESSING IN COMPUTATIONAL MOLECULAR BIOLOGY
    • G16B15/00—ICT specially adapted for analysing two-dimensional or three-dimensional molecular structures, e.g. structural or functional relations or structure alignment
    • G16B15/30—Drug targeting using structural data; Docking or binding prediction
    • G—PHYSICS
    • G16—INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR SPECIFIC APPLICATION FIELDS
    • G16B—BIOINFORMATICS, i.e. INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR GENETIC OR PROTEIN-RELATED DATA PROCESSING IN COMPUTATIONAL MOLECULAR BIOLOGY
    • G16B35/00—ICT specially adapted for in silico combinatorial libraries of nucleic acids, proteins or peptides
    • G16B35/10—Design of libraries
    • G—PHYSICS
    • G16—INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR SPECIFIC APPLICATION FIELDS
    • G16B—BIOINFORMATICS, i.e. INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR GENETIC OR PROTEIN-RELATED DATA PROCESSING IN COMPUTATIONAL MOLECULAR BIOLOGY
    • G16B40/00—ICT specially adapted for biostatistics; ICT specially adapted for bioinformatics-related machine learning or data mining, e.g. knowledge discovery or pattern finding
    • G16B40/20—Supervised data analysis
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/435—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans
    • G01N2333/575—Hormones
    • G01N2333/62—Insulins
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00—Detection or diagnosis of diseases
    • G01N2800/04—Endocrine or metabolic disorders
    • G01N2800/042—Disorders of carbohydrate metabolism, e.g. diabetes, glucose metabolism
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00—Detection or diagnosis of diseases
    • G01N2800/50—Determining the risk of developing a disease
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00—Detection or diagnosis of diseases
    • G01N2800/52—Predicting or monitoring the response to treatment, e.g. for selection of therapy based on assay results in personalised medicine; Prognosis

Landscapes

  • Life Sciences & Earth Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical & Material Sciences (AREA)
  • Molecular Biology (AREA)
  • Hematology (AREA)
  • Biomedical Technology (AREA)
  • Immunology (AREA)
  • Urology & Nephrology (AREA)
  • Physics & Mathematics (AREA)
  • Biotechnology (AREA)
  • General Health & Medical Sciences (AREA)
  • Biochemistry (AREA)
  • Medicinal Chemistry (AREA)
  • Cell Biology (AREA)
  • Analytical Chemistry (AREA)
  • Microbiology (AREA)
  • General Physics & Mathematics (AREA)
  • Pathology (AREA)
  • Food Science & Technology (AREA)
  • Spectroscopy & Molecular Physics (AREA)
  • Medical Informatics (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biophysics (AREA)
  • Theoretical Computer Science (AREA)
  • Bioinformatics & Computational Biology (AREA)
  • Evolutionary Biology (AREA)
  • Data Mining & Analysis (AREA)
  • Library & Information Science (AREA)
  • Endocrinology (AREA)
  • Software Systems (AREA)
  • Epidemiology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Artificial Intelligence (AREA)
  • Bioethics (AREA)
  • Computer Vision & Pattern Recognition (AREA)
  • Databases & Information Systems (AREA)
  • Crystallography & Structural Chemistry (AREA)
  • Evolutionary Computation (AREA)
PL20715859.3T 2019-03-28 2020-03-30 Zastosowanie folistatyny w przewidywaniu ryzyka cukrzycy typu 2 PL3948294T3 (pl)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
SE1950381 2019-03-28
PCT/EP2020/058971 WO2020193808A1 (en) 2019-03-28 2020-03-30 Use of follistatin in type 2 diabetes risk prediction

Publications (1)

Publication Number Publication Date
PL3948294T3 true PL3948294T3 (pl) 2023-10-16

Family

ID=70058386

Family Applications (1)

Application Number Title Priority Date Filing Date
PL20715859.3T PL3948294T3 (pl) 2019-03-28 2020-03-30 Zastosowanie folistatyny w przewidywaniu ryzyka cukrzycy typu 2

Country Status (13)

Country Link
US (1) US20220252615A1 (pl)
EP (1) EP3948294B1 (pl)
JP (1) JP2022526227A (pl)
KR (1) KR20210144809A (pl)
CN (1) CN114026426A (pl)
AU (1) AU2020245775A1 (pl)
BR (1) BR112021019287A2 (pl)
CA (1) CA3134929A1 (pl)
EA (1) EA202192466A1 (pl)
ES (1) ES2954164T3 (pl)
MX (1) MX2021011807A (pl)
PL (1) PL3948294T3 (pl)
WO (1) WO2020193808A1 (pl)

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1560025A3 (en) * 2003-10-03 2011-09-07 F. Hoffmann-La Roche AG Specific markers for diabetes
WO2006066263A1 (en) * 2004-12-17 2006-06-22 Entelos, Inc. Assessing insulin resistance using biomarkers
EP2030025A2 (en) * 2006-06-07 2009-03-04 Tethys Bioscience, Inc. Markers associated with arteriovascular events and methods of use thereof
US20120157378A1 (en) * 2008-11-14 2012-06-21 Simin Liu Methods and Compositions for Predicting a Subject's Susceptibility To and Risk of Developing Type 2 Diabetes
CA2778270C (en) * 2009-10-19 2021-01-05 Theranos, Inc. Integrated health data capture and analysis system

Also Published As

Publication number Publication date
EP3948294C0 (en) 2023-06-07
EP3948294A1 (en) 2022-02-09
MX2021011807A (es) 2021-10-26
BR112021019287A2 (pt) 2022-02-01
KR20210144809A (ko) 2021-11-30
JP2022526227A (ja) 2022-05-24
ES2954164T3 (es) 2023-11-20
EP3948294B1 (en) 2023-06-07
EA202192466A1 (ru) 2022-02-16
AU2020245775A1 (en) 2021-09-23
WO2020193808A1 (en) 2020-10-01
CN114026426A (zh) 2022-02-08
US20220252615A1 (en) 2022-08-11
CA3134929A1 (en) 2020-10-01

Similar Documents

Publication Publication Date Title
IL276217A (en) Use of cannabinoids in the treatment of epilepsy
SG11202109151WA (en) Merge list construction in triangular prediction
GB201810897D0 (en) Phenotype prediction
IL283372A (en) Use of cannabinoids to treat epilepsy
IL285662A (en) Use of cannabinoids to treat epilepsy
EP3903448A4 (en) PREDICTION OF USE OR COMPLIANCE
MX367312B (es) Inhibidor del eje igrbp3/tmem219 y diabetes.
MX2019013096A (es) Peptidos para el tratamiento de diabetes.
IL280876A (en) Aromatic molecules for use in the treatment of pathological conditions
HK1248810A1 (zh) 用於角膜擴張性疾病的診斷和預後的生物標記物
IL284758A (en) Use of cannabinoids to treat comorbidity related to epilepsy
PL3948294T3 (pl) Zastosowanie folistatyny w przewidywaniu ryzyka cukrzycy typu 2
MX2021005386A (es) Fragmentos de peptidos para tratamiento de diabetes.
GB201918617D0 (en) Personal lubricant composition
EP3717912A4 (en) METHODS AND MATERIALS FOR EVALUATING BIOLOGICAL AGE AND SLOWING THE PROGRESS OF EXCESSIVE BIOLOGICAL AGING
IL289371A (en) Methylthioninium for use in the treatment of synaptopathies
IL251605B (en) Use of protein in predicting intra-corporeal phenomena
GB201707207D0 (en) Treatment of type 1 diabetes
ZA202202311B (en) Novel platinum complex
IL288307A (en) Preparations for use in the treatment of insulin deficiency conditions
IL280872A (en) Aromatic molecules for use in the treatment of pathological conditions
IL284781A (en) LILRB3 binding molecules and uses thereof
EP4093420A4 (en) PERSONAL LUBRICANT CONTAINING PEPTOID
IL270788A (en) Sulfonylurea compounds in the treatment of disease associated with uv-induced damage
WO2016038040A3 (en) Dipeptidyl ketoamide compounds and their use for the treatment and/or prevention of fat accumulation